Sierra Oncology significantly expands clinical development program
Sierra Oncology reported significant progress in the advancement of its strategic pipeline of drug assets. The company announced noteworthy progress in the Dose Escalation Phase 1 portions for both of its ongoing Phase 1/2 clinical trials evaluating its potential best-in-class Chk1 inhibitor, SRA737. The company announced expansion of the efficacy-oriented Phase 2 portions of both trials, which will now target aggregate enrollment of approximately 200 patients across ten cancer indications. The company also announced it is planning to initiate a Phase 1b/2 clinical trial in the fourth quarter of 2018 that will evaluate SRA737 in combination with ZEJULA for the treatment of metastatic castration-resistant prostate cancer. In addition, the company announced it is planning to submit an Investigational New Drug for its Cdc7 inhibitor, SRA141, in the second half of 2018 in order to initiate a Phase 1/2 clinical trial, focused initially on the treatment of colorectal cancer.